A Food Effect Phase I Study of the Sulfatinib in Healthy Subjects (HMPL-012)

Inclusion Criteria: * Males , between 18 and 55 years of age, inclusive. * Body mass index (BMI) within the range of 20 to 30 kg/m2, inclusive. * In good health, determined by no clinically significant findings from medical history, physical examination, 12-lead ECG, and vital signs. * Adequate hepatic, renal, heart, and hematologic functions * Male subjects who are either sterile or agree to use and get the agreement of their sexual partners to use , during the period from informed consent until 90 days following Study Completion, 1 of the following approved methods of contraception: condom, use by female sexual partner of an intrauterine device, contraceptive sponge, diaphragm, or use of a cervical cap; or an oral, implantable, transdermal, injectable contraceptives or other contraceptive measures. * Able to comprehend and willing to sign an informed consent form (ICF). Exclusion Criteria: * disease history or clinical manifestation of any significant metabolic/endocrine, allergic, dermatological, hepatic, renal, hematological, pulmonary, immune, cardiovascular, gastrointestinal, genitourinary, neurological, or psychiatric disorder(as determined by the Investigator). * History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance, unless approved by the Investigator. * serum total bilirubin\>34.2 umol/L； * serum albumin\<35 g/L； * GFR \< 80 mL/min/1.73m2. Algorithm: GFR (mL/min/1.73m2) =186 × (SCr)-1.154 × (Age)-0.203, Scr= serum creatinine, mg/dL； * Blood pressure greater than 140/90. * History or presence of an abnormal ECG, which, in the Investigator's opinion, is clinically significant. * Smoking more than 10 cigarettes daily without intention to quit smoking during study. * History of stomach or intestinal surgery, nephrectomy, cholecystectomy or resection that would potentially alter absorption and/or excretion of orally administered drugs as determined by the investigator (appendectomy and/or hernia repair may be allowed). * Significant allergy history(eg. drug allergy); acute allergic rhinitis or food allergy within 2 weeks prior to informed consent. * Donation of blood or plasma ≥ 500 mL from 30 days prior to informed consent, or of blood or plasma ≥250 mL from 2 weeks prior to informed consent. * Receipt of blood products within 2 months prior to informed consent; * Poor peripheral venous access. * Participants who are positive for hepatitis B surface antigen (HBs antigen) or hepatitis B core antibody , hepatitis C virus (HCV) antibody; * Participants who are human immunodeficiency virus (HIV)-positive; * Diagnosis of alcoholism or drug addiction within 1 year prior to informed consent. * Participation in any other investigational drug study in which receipt of an investigational study drug occurred within 5 half-lives or 28 days, whichever is longer prior to informed consent. * Use of any prescription medications or products within 14 days prior to informed consent. * Use of any over-the-counter (OTC), non-prescription preparations (including vitamins, minerals, and phytotherapeutic, herbal,) within 7 days prior to informed consent. * Use of alcohol-, grapefruit-, Seville orange-, or caffeine-containing foods, juices, or beverages within 72 hours prior to informed consent. * Use of known hepatic or renal clearance altering agents (eg, erythromycin, cimetidine, barbiturates, phenothiazines, or herbal/plant derived preparations such as St. John's Wort, etc.) for a period of 60 days prior to first dose; * principal investigator, investigator, pharmacist, Clinical Research Coordinator or any personnel related to this study. * Any acute or chronic condition that, in the opinion of the Investigator, would limit the subject's ability to complete and/or participate in this clinical study.